Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1 25Phase NA 16Phase 1/2 16Phase 3 8Phase EARLY_PHASE1 5Phase 4 2Phase 2/3 1

Status

Completed 18Unknown 7Terminated 7Withdrawn 5Recruiting 3Not yet recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Gastrointestinal 3Breast 3Thoracic 2Sarcoma 1Genitourinary 1

Conditions

Breast Neoplasms 15Neoplasms 11Pancreatic Neoplasms 10Prostatic Neoplasms 7Glioma 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma 4Polycystic Ovary Syndrome 4Colonic Neoplasms 4Obesity 3Neoplasm Metastasis 3Multiple Myeloma 3Melanoma 3Lung Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Brain Neoplasms 3Pain, Postoperative 2Lymphoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Depression 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2

Interventions

trastuzumab biosimilar HLX02 1pertuzumab 1palbociclib 1olaparib 1niraparib 1eribulin 1entrectinib 1cobimetinib 1atezolizumab 1alectinib 1Vinorelbine 1Vemurafenib 1Trastuzumab 1Taxes 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Irinotecan 1Immunoglobulin G 1HhAntag691 1Fulvestrant 1Disulfides 1Carboplatin 1Capecitabine 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × Ovarian Neoplasms × Clear all
NCT06284226 2024-04-16

CCT-ANK-11

Beijing Kejing Biotechnology Co., Ltd.

Phase EARLY_PHASE1 Withdrawn
GastrointestinalGynecologicThoracic

Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05465590 2023-12-21

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

Mainline Biosciences, Inc.

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05368506 2023-05-06

ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02872519 2018-06-06

PET Imaging of Ovarian Carcinoma With 18F-FSPG

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡